Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
J Extracell Vesicles. 2024 Apr;13(4):e12427. doi: 10.1002/jev2.12427.
The heterogeneity of tumour cells enables cancers to dynamically adapt to microenvironmental stresses during progression. However, the mechanism underlying the transformation and intercellular communication between heterogeneous tumour cells has remained elusive. Here, we report a "contagion model" that mediates intercellular transformation between heterogeneous tumour cells which facilitates tumour progression. Initially identifying heterogeneous expression of CXCR1, a receptor for interleukin-8, in head and neck squamous cell carcinoma (HNSCC) tumour cells, we found that CXCR1 tumour cells had higher abilities for migration and invasion. Following interleukin-8-mediated activation, CXCR1 cells transformed CXCR1 cells into CXCR1 cells through the secretion of small extracellular vesicles (sEVs), which increased the proportion of CXCR1 cells and facilitated tumour progression. Mechanistically, we demonstrate that sEVs derived from interleukin-8-activated CXCR1 cells contain high levels of ATP citrate lyase (ACLY), which acetylates NF-κB p65 and facilitates its nuclear translocation to transcribe CXCR1 in CXCR1 cells. That process could be inhibited by Bempedoic acid, an FDA-approved ACLY-targeted drug. Taken together, our study reveals an sEV-mediated transformation of CXCR1 to CXCR1 cells that promotes HNSCC progression. This provides a new paradigm to explain the dynamic changes of heterogeneous tumour cells, and identifies Bempedoic acid as a potential drug for HNSCC treatment.
肿瘤细胞的异质性使癌症能够在进展过程中动态适应微环境压力。然而,异质肿瘤细胞之间转化和细胞间通讯的机制仍然难以捉摸。在这里,我们报告了一种“传染模型”,介导异质肿瘤细胞之间的细胞间转化,从而促进肿瘤进展。最初在头颈部鳞状细胞癌(HNSCC)肿瘤细胞中发现白细胞介素-8 (IL-8)受体 CXCR1 的异质表达,我们发现 CXCR1 肿瘤细胞具有更高的迁移和侵袭能力。在白细胞介素-8 介导的激活后,CXCR1 细胞通过分泌小细胞外囊泡(sEVs)将 CXCR1 细胞转化为 CXCR1 细胞,从而增加 CXCR1 细胞的比例并促进肿瘤进展。在机制上,我们证明源自白细胞介素-8 激活的 CXCR1 细胞的 sEVs 含有高水平的三羧酸循环酶(ACLY),该酶乙酰化 NF-κB p65 并促进其核转位以在 CXCR1 细胞中转录 CXCR1。该过程可被 FDA 批准的 ACLY 靶向药物 Bempedoic acid 抑制。总之,我们的研究揭示了 sEV 介导的 CXCR1 向 CXCR1 细胞的转化,促进了 HNSCC 的进展。这为解释异质肿瘤细胞的动态变化提供了新的范例,并确定 Bempedoic acid 是治疗 HNSCC 的潜在药物。